Torrent Pharmaceuticals has agreed to acquire the Styptovit-E, Finast, Finast-T, and Dynapress brands from Dr. Reddy’s Laboratories for an undisclosed price.

Styptovit-E is a gynecology product, which has an estimated market size of around INR 500 crores as per AIOCD data set. The gynecology product is expected to further bolster the presence of Torrent Pharmaceuticals in the therapy.

Finast, Finast-T, and Dynapress, are all used in the treatment of benign prostatic hyperplasia (BPH). These brands will help its presence in the urology therapy, said the Ahmedabad-based pharma company.

As per the terms of the deal, Torrent Pharmaceuticals will acquire the manufacturing, marketing, and distribution of the Styptovit-E, Finast, Finast-T, and Dynapress brands in India.

The Torrent Group expects the complete integration and transition of the four brands by June 2022.

  Ahmedabad, benign prostatic hyperplasia, Dr. Reddy’s Laboratories, Dynapress, Finast, Finast-T, India, Pharma acquisition news, Styptovit-E, Torrent Pharmaceuticals